SSelectStock
Sign in

EMCUREEmcure Pharmaceuticals Limited

Pharma · Drug Manufacturers - Specialty & Generic · NSE · as of 2026-07-20 (delayed ~30 min in market hours)

1,861.20
4.37%
76Strong

Price & Volume

Loading chart…

Key Ratios

Market Cap (₹ cr)33,823.80
P/E36.62
P/B6.83
PEG1.27
ROE %19.57
ROCE %21.20
Debt / Equity0.31
EPS48.70
Revenue Growth %16.70
Profit Growth %28.80
Dividend Yield %0.17
Promoter Holding %81.70
FII Holding %5.45
DII Holding %
Beta-0.02

“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.

Active Pattern Signals

Pullback to 21-EMALONG62%1,861.201,751.002,054.201.75
BUYConviction 85%

Why buy

  • Revenue growth: 16.7% YoY
  • Profit growth: 28.8% YoY
  • ROE: 19.6%
  • RSI: 60
  • Price vs EMA21: above
  • Price vs SMA50: above
  • Pullback to 21-EMA signal (setup quality 62%)

Bull case

  • Revenue growth: 16.7% YoY
  • Profit growth: 28.8% YoY
  • ROE: 19.6%
  • RSI: 60

Bear case

  • Dividend yield: 0.17%
  • MACD: bearish
  • Trend strength (ADX): 18
  • Volume trend: 0.6x baseline

Key risks

  • Dividend yield: 0.17%
  • MACD: bearish

Algorithmic analysis for research only — not SEBI-registered investment advice.

Trade Plan

Entry (CMP)
₹1,861.20
Stop Loss
₹1,733.49
risk 6.9%
Target 1 (1.5R)
₹2,052.76
+10.3%
Target 2 (3R)
₹2,244.33
+20.6%
Support (20d)
₹1,751.00
Resistance (52w)
₹1,944.00
Risk : Reward
1 : 1.5 → 1 : 3
risking ₹127.71/share
ATR (volatility)
₹54.48
avg daily range

Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹54.48). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.

Score Breakdown

Fundamental
85
Technical
68
Momentum
78
Risk (safety)
70

Peers — Pharma

PGHL 0.78%
84
AJANTPHARM 1.45%
82
HESTERBIO 3.09%
81
LUPIN 1.44%
80
SUNPHARMA 1.23%
80
CORONA 0.78%
79

About

Emcure Pharmaceuticals Limited provide quality and affordable healthcare solutions worldwide. It offers products in various therapeutic areas, such gynecology, anti-infectives, pain/analgesics, Vitamins, Minerals & Nutrients, blood-related, oncology, respiratory, HIV antivirals, gastro, anti-diabetic, neuro, and cardiovascular. It provides its products under Orofer XT, Tenectase, Pause, Metpure XL, Vylda, Vitanova, and Proxym brand names. Emcure Pharmaceuticals Limited has a strategic partnership with Novo Nordisk India Pvt Ltd. for the development and commercialization of Poviztra, a semaglutide injection for weight loss. Emcure Pharmaceuticals Limited was incorporated in 1981 and is based in Pune, India.